AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02151734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KALOMIN™ Tab.
Study NCT02151734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Umckamin syrup
Study NCT02420145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 12 weeks of yoga, twice weekly for 90 minutes plus a whole-day workshop
Study NCT01725386 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: Oral tablet(s) administered according to prescribing information
Study NCT00524810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Taxotere 75 mg/m² day 2 every 3 weeks
Study NCT02502487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal Penile Nerve Block
Description: Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis
Study NCT02502487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis
Study NCT02502487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine
Description: 1% Tetracaine gel instilled into urethra
Study NCT02502487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetracaine
Description: 1% Tetracaine gel instilled into urethra
Study NCT06279780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: very low-calorie diet
Description: Subjects undergo two cycles of a very-low-calorie diet (VLCD) for 6 weeks each, alternating with a hypocaloric diet (12 weeks). The dietetic intervention consists of a VLCD using a liquid formula (Optisource Plus, Nestlé S.A., Vevey, Switzerland), providing 52.8 g protein, 75.0 g carbohydrates, 13.5 g fat, 11.4 g fiber, and essential vitamins and minerals based on Recommended Dietary Allowances (RDA). This formula supplies 2738 kJ/day (654 kcal/day), replacing the participants' three daily meals. Following this and before the second VLCD cycle, a dietician performs an individualized nutritional assessment to calculate the resting energy expenditure, and personalized hypocaloric diets were prepared, reducing 500 kcal for each individual on their daily caloric expenditure, maintaining the recommended intake of each of the macronutrients (55% carbohydrates, 30% fats and 15% proteins) for 12-weeks.
Study NCT02174159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulonivirine
Description: MK-8507 administered as a single oral dose
Study NCT01705314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplements
Description: Participants will receive 7mls of D-drops (14,000U/week of vitamin D)
Study NCT01705314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 7mls of placebo drops per week for 8 months.
Study NCT01582412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral
Study NCT01582412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: oral
Study NCT03992989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Bolero M90-M
Description: The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
Study NCT03992989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Roger Select
Description: The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
Study NCT00965341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
Study NCT00965341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
Study NCT04191681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Sacubitril-valsartan at low or equivalent dose to be initiated or added to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
Study NCT03887871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal-D Tab.
Description: Harnal-D Tab. 1T single oral administration after meal
Study NCT04191681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (standard-of-care) arm
Description: Other oral vasodilator therapy to be continued or initiated to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
Study NCT03887871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chong Kun Dang Tamsulosin HCl Tab.
Description: Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration after meal
Study NCT04509583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PROFortil
Description: Multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months
Study NCT04509583 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vitamin E
Description: Only Vitamin E (Enat 400, once per day) in 3 months
Study NCT03106337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear-Wave Elastography
Description: Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
Study NCT04056117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella 4V
Description: Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
Study NCT01596218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Starting dose is 0.6 mg/kg weekly x 3
Study NCT01261715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond- liquid skin adhesive
Description: Dermabond- liquid skin adhesive
Study NCT00002537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT00002537 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01603563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care TF-CBT
Description: Stepped Care TF-CBT patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
Study NCT01603563 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard TF-CBT
Description: Standard TF-CBT patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, \& trauma narrative etc.).
Study NCT04479280 — intervention group
Intervention type: DEVICE
Intervention: Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA
Description: studying coagulation disorders in COVID19 critically ill patients
Study NCT00879996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Oral, 10-60 mg per day, 2-4 times per day, 6 months
Study NCT00879996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Sub-lingual, 4-16 mg per day, divided 2-4 times/day, 6 months
Study NCT02822560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pEVAR
Description: percutaneous femoral access using a suture-mediated closure device
Study NCT02822560 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open femoral access
Description: cutdown to femoral artery and surgical closure
Study NCT03564782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: The live, attenuated, oral (Sabin), serotype 1 poliovirus vaccine booster will be administered 1 week before PVSRIPO injection. The study drug, PVSRIPO, is the live attenuated, oral (Sabin) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 (HRV2). It will be given at a dose of 1x10\^8 TCID50 (tissue culture infectious dose) directly into the breast tumor.
Study NCT02354963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In vitro fragmentation of the ovarian tissue
Description: Unilateral ovarian cortex extraction, in vitro fragmentation and reimplantation.
Study NCT04257708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: Transvaginal us to assess the cavity
Study NCT01947660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic analgesia + Continuous regional anesthesia
Description: Systemic analgesia + Continuous regional anesthesia, peri neural for the 2 to 4 first days post-operative
Study NCT01947660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic analgesia
Description: Systemic analgesia as usual
Study NCT01047722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin ingestion followed by doing a Bleeding Volume Test
Description: Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
Study NCT04056117 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: MenACWY
Description: Control vaccine administrated to adults and infants
Study NCT04056117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY
Description: Control vaccine administrated to adults and infants
Study NCT04056117 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rabies
Description: Control vaccine administrated to children
Study NCT01047722 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gatorade Placebo followed by Bleeding Volume Test.
Description: Patient drinks a glass of Gatorade, then one hour later a bleeding volume test is performed.
Study NCT01372605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement-Based Care collaborative depression management
Description: Depression Care Manager collects metrics on depressive severity and side effects and provides decision support regarding antidepressant initiation and modification to HIV providers who prescribe medications
Study NCT01372605 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Usual Care
Study NCT01097252 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation with cisplatin 40mg/m2, 6 cycles, every week
Study NCT01097252 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: radiation with cisplatin 40mg/m2, 6 cycles, every week
Study NCT01097252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: weekly cisplatin
Description: weekly cisplatin 40mg/m2, 6 cycles
Study NCT01097252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tri-weekly cisplatin
Description: cisplatin 75mg/m2, 3cycles, every 3 weeks
Study NCT03928145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25 mg
Description: Chlorthalidone 25 mg taken orally in the morning for 12 weeks.
Study NCT03928145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg
Description: Chlorthalidone 25 mg taken orally in the morning for 12 weeks.
Study NCT03928145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 50 mg
Description: Hydrochlorothiazide 50 mg taken orally in the morning for 12 weeks.
Study NCT03928145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride 20 mg
Description: Amiloride 20 mg taken orally in the morning for 12 weeks.
Study NCT03928145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride 20 mg
Description: Amiloride 20 mg taken orally in the morning for 12 weeks.
Study NCT03928145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride 10 mg
Description: Amiloride 10 mg taken orally in the morning for 12 weeks.
Study NCT04056117 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Diphtheria, Tetanus and Pertussis (DTaP)
Description: Control vaccine administrated to infants
Study NCT04056117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control administrated to adults
Study NCT02183116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Study NCT01720823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: home polysomnography (GETEMED)
Study NCT01720823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard polysomnography (BRAINNET II)
Study NCT01339598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (Eldith DC Stimulator)
Description: Eldith DC Stimulator (NeuroConn GmbH, Germany)
Study NCT01339598 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (Eldith DC Stimulator)
Description: Eldith DC Stimulator (NeuroConn GmbH, Germany)
Study NCT04372160 — intervention group
Intervention type: OTHER
Intervention: Dietary assessment
Description: 24-hr dietary recall
Study NCT03705455 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ISAP SMS
Description: ISAP SMS is a text message for caregivers use that provides immunization schedule and vaccine availability at the nearest immunization clinic.
Study NCT01167686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gardemont Goldtrain Plus (GT+)
Description: Four tablets of 760 mg of GT+ administered three times a day for seven consecutive days and similar placebo tablets given to the control arm
Study NCT04266288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Active drug
Study NCT04266288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Placebo
Study NCT00572338 — intervention group
Intervention type: OTHER
Intervention: No drugs are involved
Description: No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
Study NCT02544802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-Derived Mesenchymal Stem Cells
Study NCT00779558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sulfate infusion at 10 units/kg/hour
Description: Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery
Study NCT00779558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Infusion of normal saline
Study NCT00980005 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK1557482A
Description: One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
Study NCT00980005 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone®
Description: One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
Study NCT02378519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-prog, followed by CBT + PT
Description: This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
Study NCT02378519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Base, followed by Web + CBT + PT
Description: The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
Study NCT05707611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Running
Description: The participant perform running on treadmill at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
Study NCT05707611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling
Description: The participant perform cycling on cycle ergometer at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
Study NCT05707611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swimming
Description: The participant perform swimming at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
Study NCT01973036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley Catheter
Description: The balloon will be inflated with 30 cc of sterile saline. The catheter will be taped to the patient's leg so that traction is maintained. The catheter will be assessed hourly for expulsion by a health care provider by applying gentle traction on the catheter or a vaginal examination if it is unclear by traction. Once the Foley catheter is expelled or 12 hours reached, the induction will be continued with oxytocin per this protocol.
Study NCT01973036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
Study NCT01973036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
Study NCT03108729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Eslicarbazepine acetate tablets, taken once daily for 1 year. The daily maintenance dose will be within the range of 300 mg to 1600 mg ESL, and is determined by body weight, clinical response and tolerability.
Study NCT04106843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV
Study NCT02082626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Study NCT03357367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TiVi system
Description: Device: TiVi system A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by TiVi system 10 minutes later.~Measurement of the value of skin blood flow (by TiVi system) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded
Study NCT00869882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumferential arthrodesis
Description: Patients are carefully positioned in the proned position and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs which can be performed at surgeon's demand during the whole surgery time.~The preceding procedure is performed. In case of foraminal stenosis, decompression is performed at the same time as discal approach via the narrowest foramen.~In addition to this, before preparation of bed for bone grafting, nerve roots are retracted and the disc nucleus is removed entirely, then endplate decortication is performed. The disc space is distracted. The most anterior part of the disc space is packed with cancellous bone. A cage packed with bone is inserted into the anterior portion of the interspace. According to cage location, bone graft could be inserted in the posterior portion of the interspace. Cage placement is radiologically checked.~The end of the procedure is the same as for GPLI.